ProShares Bitcoin ETF vs Regeneron Pharmaceuticals Inc — how do they compare? ProShares Bitcoin ETF trades at $8.77, while Regeneron Pharmaceuticals Inc trades at $655.5 (market cap $68.79B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.57% dividend while ProShares Bitcoin ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, ProShares Bitcoin ETF nearer its low. Which is the better fit depends on your goals.
| BITO | REGN | |
|---|---|---|
Sector | Crypto-linked | Health |
52-Week High | $22.93 | $812.27 |
52-Week Low | $7.98 | $542.52 |
Market Cap | — | $68.79B |
Enterprise Value | — | $62.74B |
Dividend Yield | — | 0.57% |
Signals from Pluang's Aura AI — not financial advice
BITO trades at $8.44, down 2.65% today amid bearish technical signals with 12 sell indicators versus 4 buy signals. The ETF faces challenges with declining distributions and negative sentiment as crypto markets struggle. Recent dividend payments of $0.01-$0.02 per share provide limited offset to the fund's 24.26% five-year decline.
The outlook remains cautious with structural costs and Bitcoin correlation concerns weighing on performance. Key risks include management fee drag, distribution volatility, and crypto market exposure. Investors should monitor fee structure efficiency and Bitcoin market stability for potential recovery catalysts.
Regeneron (REGN) trades at $663.09, down slightly by 0.22% on the day, with a bullish technical signal supported by moving averages. The company maintains strong profitability, with a net income margin of 29.65% and consistent earnings beats in recent quarters. Recent positive news includes FDA and EMA acceptance of its cemdisiran application for gMG and selection for an FDA pilot program to accelerate manufacturing reviews, highlighting operational momentum.
The outlook remains positive given analyst consensus with a $764.50 price target and no sell ratings, though risks include regulatory hurdles and competitive pressures in biotech. Earnings growth and pipeline advancements are key catalysts, but investors should weigh high RSI levels suggesting potential near-term overbought conditions against strong fundamental performance.
Trailing returns across standard periods
Latest headlines on both assets
BITO offers exposure to Bitcoin returns primarily through Bitcoin futures contracts. It provides a regulated way for investors to trade Bitcoin performance within a traditional brokerage account without direct ownership.
Read more on BITO →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →